What Accelerated Biosciences does

Accelerated Biosciences is a regenerative medicine company that has built a proprietary platform around human trophoblast stem cells (hTSCs), which were originally isolated in 2003 by founder Jau-nan Lee from chorionic villi tissue obtained during a salpingectomy procedure. The company serves biopharmaceutical companies (from early-stage startups to established enterprises) and academic research institutions, supplying ethically sourced starting materials, iPSC products, exosomes, and genetically engineered platforms for therapeutic development, cell therapy, antibody production, and biomanufacturing applications. The company is incorporated in Delaware, headquartered in Philadelphia, PA, and operates cell-sourcing and exosome manufacturing in Taiwan.

The company's core offering is a platform-plus-products architecture anchored on the hTSC line, which is naturally immune privileged, genetically stable, and capable of 85x population doublings (theoretically producing up to 3.87x10^25 cells). The catalog includes hTSC RUO cell lines (ABX-001, ABX-002, ABX-003), hTSC-derived iPSCs (ABX-005, ABX-006) reprogrammed via an mRNA method without Yamanaka factors, hTSC-derived exosomes (ABX-004) produced in xeno-free 3D bioreactor systems, and two genetically engineered platforms — GEMS (up to 10 precision cutting sites for cell therapy, mAb, and viral vector applications) and CHO-GEMS (pre-engineered multi-specific antibody production). The platform is supported by 15 GMP-eligible cell lines and a patent portfolio of 54 granted patents and 46 pending applications across 12 families. Cells are sourced and processed under current Good Tissue Practice (cGTP) and conform to Global Ethical Standards and Clinical Cell Regulations.

The business model rests on three revenue streams: (1) sale of cell line products as Research Use Only (RUO) reagents with corresponding GMP-grade options available under commercial license, (2) licensing of hTSC technology and derived platforms to biopharma partners, and (3) GMP/CMC services delivered in collaboration with Theragent and Dark Horse Consulting. GTM is enterprise field sales driven by partnership inquiries through the company website, supplemented by attendance at industry conferences (ARM Meeting on the Mesa, BioJapan, Wilson Sonsini Biotech Summit, ISEV) and the company's own Trophoblast Stem Cell Forum series. In July 2025, the company formalized an exclusive US distributorship with Summit Pharmaceuticals International. The leadership team comprises CEO Yuta Lee, CFO Phillip King, CSO Sicco Popma (formerly Johnson & Johnson and UPenn), and COO Justin Hu, with Jau-nan Lee serving as Chairman.

Name

Accelerated Biosciences

Legal name

Accelerated Biosciences, Inc.

Website

https://acceleratedbio.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Accelerated Biosciences is a regenerative medicine company that develops a proprietary human trophoblast stem cell (hTSC) platform, supplying ethically sourced cell lines, iPSCs, exosomes, and genetically engineered platforms to biopharma companies and academic institutions for therapeutic development.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines) (HLAGAGAI)

Keywords

• Regenerative medicine
• Stem cell research
• Cell line products
• Biopharmaceutical licensing
• GMP cell manufacturing

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Cell Line Products: Sale of hTSC, iPSC, and exosome products as Research Use Only (RUO) reagents. Products include ABX-001 through ABX-006 with corresponding GMP options available under commercial license.
2. Licensing and IP: Licensing of hTSC technology and derived platforms to biopharma partners. Offers clear IP protection and global freedom-to-operate at attractive license terms.
3. GMP/CMC Services: De-risked starting material GMP and CMC issues for partners, with collaboration with Theragent and Dark Horse Consulting Group.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Accelerated Biosciences develops and supplies ethically sourced human trophoblast stem cell (hTSC) starting materials and derived genetically engineered platforms for regenerative medicine and biomanufacturing. Its product portfolio includes hTSC cell lines (ABX-001 to ABX-003), hTSC-derived iPSCs (ABX-005, ABX-006), hTSC-derived exosomes (ABX-004), and engineered platforms (GEMS and CHO-GEMS), sold as Research Use Only reagents with corresponding GMP-grade options available under commercial license to biopharma and academic partners.

Product overview

Accelerated Biosciences offers a platform-plus-products architecture centered on its patented human trophoblast stem cell (hTSC) technology. The core hTSC Platform provides 15 GMP-eligible cell lines and corresponding RUO cell lines (ABX-001, ABX-002, ABX-003) as the foundational starting material for regenerative medicine. From this platform, the company derives iPSC products (ABX-005, ABX-006) using mRNA reprogramming without Yamanaka factors, and exosome products (ABX-004). The genetically engineered platforms include GEMS for precision genetic editing supporting cell therapy, mAB, and viral vector development, and CHO-GEMS for pre-engineered antibody production. All products are ethically sourced from chorionic villi tissue.

Differentiator

Problem solved

Functional benefit

Products and services

• ABX-001 hTSC 2003 RUO Primary human trophoblast stem cells (hTSC) derived from chorionic villi (pre-placental tissue, female, Asian, approximately 6-8 weeks post-fertilization) with >70% viability post-thaw. Sold as Research Use Only with corresponding GMP cells available under commercial license to biopharma and academic researchers.
• ABX-002 hTSC 1810 RUO Primary human trophoblast stem cells (hTSC) obtained and cultured under current Good Tissue Practice (cGTP) and conform to Global Ethical Standards and Clinical Cell Regulations. Guaranteed >70% viability post-thaw. Research Use Only with corresponding GMP cells available under commercial license.
• ABX-003 hTSC 1905 RUO Primary human trophoblast stem cells (hTSC) obtained and cultured under cGTP. Female, Asian, approximately 6-8 weeks post-fertilization. Approximately 1 million cells per standard bank vial. Research Use Only with corresponding GMP cells available under commercial license.
• ABX-004 hTSC-derived Exosomes Exosomes enriched from human trophoblast stem cells and xeno-free media. Produced by GMP hTSC expansion using a 3D bioreactor system. Available frozen at 1x10^10 particles/ml or lyophilized. Manufactured in Taiwan or USA. Research Use Only with commercial license available.
• ABX-005 hTSC 2003-derived iPSC Clone C1 Induced Pluripotent Stem Cells (iPSC) derived from human trophoblast stem cells using mRNA method without Yamanaka factors. Manufactured by CDMO partner (Pluristyx) per standard operating procedures. 46, XX karyotype. Guaranteed >70% viability post-thaw. Research Use Only.
• ABX-006 hTSC 2003-derived iPSC Clone C6 Induced Pluripotent Stem Cells (iPSC) derived from human trophoblast stem cells using mRNA method without Yamanaka factors. 46, XX karyotype, pluripotency markers OCT4, SSEA-4, NANOG, SOX2. Manufactured in USA by Pluristyx, Inc. Research Use Only with GMP cells under commercial license.
• GEMS (Genetically Engineered Modification System) Genetically engineered platform allowing precision complex genetic editing without random insertion for combination cell therapy, mAB, viral vector, and complex protein production. Features up to 10 engineered cutting sites, integrates with any cell line using any editing methods, and supports proof of concept for CAR, mAB, growth regulators, and safety switches.
• CHO-GEMS Pre-engineered antibody production platform designed for complex, multi-specific antibodies. Pre-designed cutting sites enable rapid prototyping of antibody designs. Pre-integrated with leading CDMOs for cost-effective transition from research to commercialization, with experienced cell-line development specialists supporting customers.
• hTSC Platform (licensing and IP package) Patented human trophoblast stem cell (hTSC) platform offering core intellectual properties, protocols, and process designs. Includes 15 GMP-eligible cell lines and corresponding RUO cell lines, with global freedom-to-operate at attractive license terms. Naturally immune privileged and genetically stable with exceptional expansion capacity.

Quantifiable outcome

• 85x population doublings capability
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core.

• Summit Pharmaceuticals InternationalcoreChannel Partner/ Reseller/ Distributor · 15 July 2025Signed an exclusive distributorship agreement with Summit Pharmaceuticals International, a US cell provider, expanding distribution reach in the US market.
• StemmatterscoreStrategic or Co-development Partner · 16 December 2024Accelerated Biosciences and Stemmatters collaborated to offer iPSC derived from human trophoblast stem cells. This partnership combines Accelerated Bio's hTSC platform with Stemmatters' expertise in iPSC differentiation.
• PluristyxcoreStrategic or Co-development Partner · 11 July 2024Accelerated Bio and Pluristyx created Clinical Grade Induced Pluripotent Stem Cells from reprogramming human trophoblast stem cells. Pluristyx serves as the CDMO manufacturer for iPSC products (ABX-005, ABX-006).
• Wistar InstitutecoreStrategic or Co-development Partner · 10 July 2024Revolutionizing Cancer Treatment: Wistar and Accelerated Biosciences collaborate to pioneer transformative immune cell therapies leveraging the hTSC platform.
• Agathos BiologicscoreOEM/ Whitelabel/ Licensing Partner · 5 June 2024License of human trophoblast stem cells (hTSC) to Agathos Biologics for development of ethically sourced research and biomanufacturing platforms.
• SpanioscoreStrategic or Co-development Partner · 16 May 2024Accelerated Biosciences and Spanios partner to advance therapeutic design across solid tumor cancers, leveraging hTSC-derived platforms.
• MekonoscoreStrategic or Co-development Partner · 2 May 2024Mekonos entered partnership agreement with Accelerated Biosciences to develop and commercialize engineered human trophoblast stem cells (hTSCs) for biomanufacturing applications.
• TheragentcoreImplementation/ SI/ Consulting PartnerTheragent oversees GMP and CMC processes for Accelerated Biosciences, ensuring consistent product quality and manufacturing standards.
• Dark Horse Consulting GroupcoreImplementation/ SI/ Consulting PartnerDark Horse Consulting Group provides assurance as to manufacturing capabilities and suitability of source material for Accelerated Biosciences.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• FUJIFILM Cellular Dynamics: FUJIFILM Cellular Dynamics is a leading commercial supplier of iPSC-derived cells and tissues used for drug discovery, cell therapy, and regenerative medicine research. Directly comparable as a starting-material/cell-line platform vendor to biopharma and academia.
• STEMCELL Technologies: STEMCELL Technologies is a major developer and supplier of cell culture media, reagents, and cell isolation products supporting stem cell research and cell therapy development. Comparable as a stem cell research tools and reagents provider serving biopharma and academic customers.
• Pluristyx: Pluristyx is an iPSC-focused CDMO and iPSC line developer that manufactures clinical-grade iPSCs, including ABX's hTSC-derived iPSC products. Comparable as an iPSC platform/CDMO serving regenerative medicine developers.

Broad incumbents

• Lonza Cell & Gene Technologies: Lonza is a global CDMO and cell therapy manufacturing platform serving cell and gene therapy developers worldwide. Comparable as a broad incumbent providing GMP manufacturing services and cell therapy starting materials to biopharma.
• Thermo Fisher Scientific (Gibco Cell Culture): Thermo Fisher's Gibco business is a dominant supplier of cell culture media, reagents, and primary cells used in regenerative medicine and cell therapy. Comparable as a broad incumbent life sciences tools vendor serving overlapping biopharma customers.
• Cytiva (Danaher): Cytiva supplies bioprocessing technologies, single-use systems, and cell therapy manufacturing solutions to the regenerative medicine industry. Comparable as a broad incumbent providing tools and infrastructure for cell therapy and biomanufacturing customers.

Emerging players

• Cynata Therapeutics: Cynata is a clinical-stage company developing iPSC-derived MSC therapies for inflammatory and immune-mediated diseases. Comparable as a regenerative medicine player leveraging iPSC/pluripotent starting materials to develop cell therapies.
• Fate Therapeutics: Fate Therapeutics is a clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell cancer immunotherapies. Comparable as a regenerative medicine player using iPSC/pluripotent platforms for cell therapy development.
• Century Therapeutics: Century Therapeutics is a clinical-stage company developing iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases. Comparable as a regenerative medicine player using iPSC starting materials for off-the-shelf cell therapies.
• Mesoblast: Mesoblast is a commercial-stage regenerative medicine company developing mesenchymal lineage cell therapies for inflammatory and cardiovascular diseases. Comparable as a stem cell-based therapeutic developer targeting similar regenerative medicine indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/accelerated-biosciences-corp.

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accelerated Biosciences